Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis

Rheumatology (Oxford). 2019 Dec 1;58(12):2333-2335. doi: 10.1093/rheumatology/kez229.

Authors

Eline Houben^{1

2}, Arielle Mendel³, Joost W van der Heijden⁴, Suat Simsek¹, Willem A Bax¹, Simon Carette³, Alexandre E Voskuyl², Christian Pagnoux³, Erik L Penne¹

Affiliations

¹ Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
² Department of Rheumatology, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
³ Vasculitis Clinic, Department of Medicine, Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada.
⁴ Department of Nephrology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.

PMID: 31243446
DOI: 10.1093/rheumatology/kez229

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / complications*
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology
Antibodies, Antineutrophil Cytoplasmic / immunology*
Canada / epidemiology
Cardiovascular Diseases / epidemiology*
Cardiovascular Diseases / etiology
Cardiovascular Diseases / therapy
Disease Management*
Female
Guideline Adherence*
Humans
Male
Middle Aged
Netherlands / epidemiology
Prevalence
Risk Assessment / methods*
Risk Factors

Substances

Antibodies, Antineutrophil Cytoplasmic